Last reviewed · How we verify

NCT05404425: NIEPCE

Non-severe Traumatic Injuries Evaluation Using smartPhone Camera for Extra-hospital Regulation

Completed NA Last updated 18 November 2023
What this trial tests

NA trial testing Visioconference: live visual injury evaluation in Mild Traumatic Injury in 168 participants. Completed in 30 October 2023.

Timeline
8 July 2022
Primary endpoint
19 October 2023
30 October 2023

Quick facts

Lead sponsorPoitiers University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment168
Start date8 July 2022
Primary completion19 October 2023
Estimated completion30 October 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Poitiers University Hospital

Who can join

18 and older, any sex, with Mild Traumatic Injury or Pre-hospital Dispatching. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Photography teletransmission allow a better and optimized dispatching of patients calling an Emergency Medical Call Center (EMCC) for a mild traumatic injury. It has previously been studied for patients to whom an ambulance was sent and therefore presumed to be older or with co-morbidities. The present trial aim to evaluate in the general population, the effect of a smartphone-mediated visioconference in the dispatching of patients calling an EMCC for mild traumatic injury.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Poitiers University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05404425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing